Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) has emerged as a notable player in the biopharmaceutical sector, leveraging its FDA-approved oncology drug LYMPHIR (denileukin diftitox-cxdl) to establish a commercial presence while advancing a diversified pipeline targeting critical care indications. The company's strategic focus on first-in-class therapies addresses significant unmet medical needs, positioning it for potential growth and value creation.
LYMPHIR, approved by the U.S. Food and Drug Administration in August 2024, is a targeted immunotherapy for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Following its commercial launch in December 2025, LYMPHIR generated $5.6 million in net product revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. This initial commercial success is underscored by broad payer coverage, with nearly 100% of covered commercial lives and 83% of targeted accounts achieving formulary inclusion or under active review as of May 2026. The company has also begun expanding LYMPHIR's reach internationally, with an initial shipment to Europe in April 2026. Beyond CTCL, Citius is exploring additional oncology applications, including investigator-initiated studies combining LYMPHIR with pembrolizumab for recurrent or refractory gynecologic cancers and with CD19-directed CAR-T therapy for high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026.
Citius's late-stage pipeline includes Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients. Mino-Lok met primary and secondary endpoints in a pivotal Phase 3 superiority trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The company holds worldwide rights through a license from The University of Texas MD Anderson Cancer Center. Following a Type C meeting with the FDA, Citius received guidance outlining a pathway to support a future New Drug Application submission. Investor materials estimate worldwide sales potential of approximately $1.8 billion for Mino-Lok.
Another key asset is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for symptomatic treatment of hemorrhoids. Approximately 10 million people in the U.S. report hemorrhoid symptoms annually, yet no FDA-approved prescription products exist for this indication. If approved, Halo-Lido could become the first such product. The company completed a Phase 2b study in 2023 and has met with the FDA to discuss next steps.
Citius is also developing a stem cell platform using induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. In a proof-of-concept sheep model, interim results showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls. Additional studies are warranted to inform future human clinical trials.
The company's leadership brings extensive experience in pharmaceutical development, commercialization, and sales. Leonard Mazur, Co-Founder, CEO, and Chairman, has approximately five decades of industry experience, having founded and sold several pharmaceutical companies. Myron Holubiak, Co-Founder and Executive Vice Chairman, previously served as president of Roche Laboratories and held multiple sales and marketing roles during a 19-year career with Roche.
Citius's strategy combines a revenue-generating commercial product with multiple late-stage development programs, providing several potential catalysts. As the company continues to engage with the FDA on Mino-Lok and Halo-Lido and expands LYMPHIR's indications and geographic reach, it is well-positioned to address critical care needs and create value for stakeholders. For more information, visit https://www.citiuspharma.com/.
